The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.
Discover the best professional documents and content resources in AnyFlip Document Base.
Search
Published by , 2016-04-26 13:12:43

ALSP2014-4_Portfolio

ALSP2014-4_Portfolio

Advanced Life Settlement

Portfolio 2014-4, LLC



ALSP 2014-4, LLC


Table of Contents




BDO Agreed Upon Procedures 3-6

ALSP 2014-4 Fund Summary 7

Policy Status Report – 21st Services 8

Hewett, Policy 1269 9-17
Life Expectancy - 21st & AVS
Proof of Ownership – TransAmerica


Greenberg, Policy 1260 18-26
Life Expectancy - 21st & AVS
Proof of Ownership – Phoenix


Mullinix, Policy 1272 27-37
Life Expectancy - 21st & AVS
Proof of Ownership – TransAmerica


Wolfson, Policy 1271 38-47
Life Expectancy - 21st & AVS
Proof of Ownership – American National


Cerullo, Policy 1273 48-57

Life Expectancy - 21st & LSI (Longevity Services, Inc.)

Proof of Ownership – Allianz


Palacci, Policy 1258 58-63
Life Expectancy - 21st
Proof of Ownership – Ameritas





All information provided in this book is for internal use only. The information included is confidential, proprietary

and not meant for public dissemination. Some of the information in this book has been redacted in order to maintain

the privacy of the insureds.

3

CONFIDENTIAL, NOT TO BE DUPLICATED

4

CONFIDENTIAL, NOT TO BE DUPLICATED

5

CONFIDENTIAL, NOT TO DUPLICATED

6

CONFIDENTIAL, NOT TO BE DUPLICATED

ALSP 2014-4 Fund Summary

Insured Last Name Policy ID: Face Acquisition Gender: Insurance Current Average ROI Premium Months
1258 Amount: Cost: Rating: Age*: LE: at LE: & Servicing Escrowed:
Palacci Escrowed:
Greenberg $3,500,000.00 $1,700,863.53 Female A+ 85.1 92 6.77 48
$527,134.00 36
Hewett 60
Wolfson 1260 $2,000,000.00 $1,193,075.29 Male B+ 85.3 47 14.04 $446,755.00 72
Mullinix 36
Cerullo 1269 $10,000,000.00 $6,818,355.29 Male A+ 82.3 59 9.50 $1,896,002.00 60

1271 $7,000,000.00 $3,499,101.18 Male A 83.8 64 14.01 $221,636.00

1272 $2,500,000.00 $1,923,764.71 Male A+ 89.5 30 11.05 $2,600.00

1273 $8,500,000.00 $5,990,161.58 Female A 85.3 72 5.90 $2,061,875.00

Total Face Amount: $33,500,000.00
$21,125,321.58
Total Acquisition Costs:
47.67%
Average Acquisition Cost
(Excluding Premium & $5,156,002.00
85.2
Servicing):
Total Premium & Servicing

Escrowed:
Average Age:

Average LE: 60.7

Weighted ROI: 9.19%

*Current age calculated as of March 31st, 2016

The above projections are for demonstrative purposes only. Projections and actual returns of ALSP 2014-4 and future funds will vary depending on the performance of the policies in each specific fund.

CONFIDENTIAL, NOT TO BE DUPLICATED

7

Policy Status ASR Alternative Investments, LP

Generation Date: 21-Mar-2016

Policy Standing Count Face
Good
Grace 8 $48,500,000
Total
0 $0

8 $48,500,000

21st Policy ID Policy Number Insured Name Carrier Face Amount Effective Date Standing

15973 Klein American National Insurance Company $5,000,000.00 15-Jul-2008 Good
16974 Good
15208 Wolfson American National Insurance Company $7,000,000.00 19-Mar-2007 Good
16964 Good
13704 Rosenberg Lincoln National Life Insurance Company $10,000,000.00 21-Nov-2007 Good
17059 Good
13733 Mullinix Transamerica Life Insurance Company $2,500,000.00 03-Aug-1990 Good
15948 Good
Greenberg PHL Variable Insurance Company $2,000,000.00 08-Nov-2007
Cerullo $8,500,000.00 28-Dec-2010
Palacci Allianz Life Insurance Company of North $3,500,000.00 04-May-2009
America

Union Central Life Insurance Company

Hewett Transamerica Life Insurance Company $10,000,000.00 17-Jan-2003

CONFIDENTIAL, NOT TO BE DUPLICATED

8

Policy ROI Illustration Hewett

Date Calculator Prepared: Months Underwriter 4/1/2015
Policy ID: 50 21 ST ALSP2014-1269
68 AVS
LE 1 Multiplier
LE 2
LE 3 7.25
190

Full Policy Details

Insurance Company: TransAmerica
Company Rating: A+
Type of Death Benefit:
Face Amount (Death Benefit): FDB
Leveled or Optimized Annual Premium Expense: $10,000,000
Annual Premium Expense (Year 1):
DOB of Insured: Optimized
Age as of Date Prepared: $88,836
Gender:
Longest LE (In Months): 1934
Average LE (In Months): 81.3
Male
68
59

Purchase Details

Years Escrowed For Premiums (Estimated): 5
Premiums Paid Through Date: 4/1/2020
Acquisition Cost: $6,818,355
Acquisition Cost as a Percentage of Face Amount: 68.18%

Estimated Return Including Premium Refunds/Calls

Cost (Includes Amount Paid
Upon Maturity
Year Year Insured Age Escrow (Includes Escrow Gain/ Loss Yearly IRR

1 Reserve) Reserve) 94.67%
2 36.03%
3 2016 82.3 $ (6,818,355) $ 11,613,463 $ 4,795,108 20.54%
4 13.39%
5 2017 83.3 $ (6,818,355) $ 11,247,542 $ 4,429,187 9.22%
6 6.45%
7 2018 84.3 $ (6,818,355) $ 10,856,636 $ 4,038,281 4.44%
8 2.91%
9 2019 85.3 $ (6,818,355) $ 10,443,469 $ 3,625,114 1.68%
10 0.64%
2020 86.3 $ (6,818,355) $ 10,000,000 $ 3,181,645 9.50%

2021 87.3 $ (7,294,430) $ 10,000,000 $ 2,705,570

2022 88.3 $ (7,805,299) $ 10,000,000 $ 2,194,701

2023 89.3 $ (8,348,425) $ 10,000,000 $ 1,651,575

2024 90.3 $ (8,922,459) $ 10,000,000 $ 1,077,541

2025 91.3 $ (9,544,382) $ 10,000,000 $ 455,618

LE (in Months) 59

The above chart is for illustrative purposes only. It should be used as a reference and no specific Return On Investment (“ROI”) is guaranteed or
implied. All calculations rely on assumptions about future circumstances. Actual returns may vary if the relied upon circumstances are not accurate.

Confidential Medical Summary

The Insured is an 81.3 year old male with a history of stage II prostate cancer. In 2005 he was diagnosed
with Coronary artery disease and has had bypass grafting and /or angioplasties/stents in the last ten
years. He has hypertension, diabetes and suffers from mild depression and anxiety. A 2015 study shows
significant stenosis of the internal and external carotid arteries. He has a BMI of 22.2, current use of
tobacco includes pipes and cigars. He functions with weakness and fatigue. Current medications include;
Vicodin, Xanax, Zocor and Ambien.

9 CONFIDENTIAL, NOT TO BE DUPLICATED

10 CONFIDENTIAL, NOT TO BE DUPLICATED

11 CONFIDENTIAL, NOT TO BE DUPLICATED

12 CONFIDENTIAL, NOT TO BE DUPLICATED

13 CONFIDENTIAL, NOT TO BE DUPLICATED

14 CONFIDENTIAL, NOT TO BE DUPLICATED

15 CONFIDENTIAL, NOT TO BE DUPLICATED

CONFIDENTIAL, NOT TO BE DUPLICATED

16

CONFIDENTIAL, NOT TO BE DUPLICATED

17

Policy ROI Illustration Greenberg

Date Calculator Prepared: Months Underwriter 11/17/2014
Policy ID: 42 21 ST ALSP2014-1260
52 AVS
LE 1 Multiplier
LE 2
LE 3 12.23
295

Full Policy Details

Insurance Company: PHL Variable
Company Rating: B+
Type of Death Benefit:
Face Amount (Death Benefit): FDB
Leveled or Optimized Annual Premium Expense: $2,000,000
Annual Premium Expense (Year 1): Optimized
DOB of Insured: $123,846
Age as of Date Prepared:
Gender: 1931
Longest LE (In Months): 83.9
Average LE (In Months): Male
52
47

Purchase Details

Years Escrowed For Premiums (Estimated): 3
Premiums Paid Through Date: 11/17/2017
Acquisition Cost: $1,193,075
Acquisition Cost as a Percentage of Face Amount:
59.65%

Estimated Return Including Premium Refunds/Calls

Year Year Insured Cost (Includes Amount Paid Gain/ Loss Yearly IRR
Age Escrow Reserve) Upon Maturity
1 (Includes Escrow $ 1,125,034 139.00%
2 2015 84.9 $ (1,193,075) $ 930,561 43.43%
3 2016 85.9 $ (1,193,075) Reserve) $ 806,925 22.66%
4 2017 86.9 $ (1,193,075) $ 2,318,109 $ 674,718 13.48%
5 2018 87.9 $ (1,325,282) $ 2,123,636 $ 546,044 8.43%
6 $ 2,000,000 $ 422,106 5.29%
7 2019 88.9 $ (1,453,956) $ 2,000,000 $ 287,428 3.03%
8 2020 89.9 $ (1,577,894) $ 108,193 0.99%
2021 90.9 $ (1,712,572) $ 2,000,000 14.04%
2022 91.9 $ (1,891,807) $ 2,000,000
$ 2,000,000
LE (in Months) $ 2,000,000

47

The above chart is for illustrative purposes only. It should be used as a reference and no specific Return On Investment (“ROI”) is guaranteed or
implied. All calculations rely on assumptions about future circumstances. Actual returns may vary if the relied upon circumstances are not accurate.

Confidential Medical Summary

The insured is a 83.6 year old male with stage III Lymphoma, Diabetes, Hypertension and degenerative vascular
disease. He has Diverticulosis, mild renal insuffiencies and a history of kidney stones. He suffers from age
related ocular issues including, cataracts, glaucoma, macular degeneration and retina tear. He has had multiple
surgeries of the spine and continues to suffer from Osteoarthritis, Significant spinal disc desease, Stenosis and
Sciatica. Former smoker and currently maintains responsible alcohol use. His body mass index(BMI) is 34.3.

CONFIDENTIAL, NOT TO BE DUPLICATED

18

CONFIDENTIAL, NOT TO BE DUPLICATED

19

20 CONFIDENTIAL, NOT TO BE DUPLICATED

21 CONFIDENTIAL, NOT TO BE DUPLICATED

CONFIDENTIAL, NOT TO BE DUPLICATED

22

CONFIDENTIAL, NOT TO BE DUPLICATED

23

CONFIDENTIAL, NOT TO BE DUPLICATED

24

25 CONFIDENTIAL, NOT TO BE DUPLICATED

26 CONFIDENTIAL, NOT TO BE DUPLICATED

Policy ROI Illustration Mullinix

Date Calculator Prepared: Months Underwriter 10/14/2015
Policy ID: 29 21 ST ALSP2014-1272
30 AVS
LE 1 Multiplier
LE 2
LE 3 21.82
305

Full Policy Details

Insurance Company: TransAmerica
Company Rating: A+
Type of Death Benefit:
Face Amount (Death Benefit): FDB
Leveled or Optimized Annual Premium Expense: $2,500,000
Annual Premium Expense (Year 1): Optimized
DOB of Insured:
Age as of Date Prepared: $0
Gender: 1926
Longest LE (In Months):
Average LE (In Months): 89.0
Male

30
30

Purchase Details

Years Escrowed For Premiums (Estimated): 0
Premiums Paid Through Date: 10/14/2015
Acquisition Cost: $1,923,765
Acquisition Cost as a Percentage of Face Amount:
76.95%

Estimated Return Including Premium Refunds/Calls

Amount Paid

Year Year Insured Cost (Includes Upon Maturity Gain/ Loss Yearly IRR
Age Escrow Reserve) (Includes Escrow
1 $ 576,235 29.95%
2 Reserve) $ 576,235 14.00%
3 $ 576,235 9.13%
4 2016 90.0 $ (1,923,765) $ 2,500,000 $ 520,295 6.15%
5 $ 320,814 3.08%
6 2017 91.0 $ (1,923,765) $ 2,500,000 $ 106,303 0.86%
11.05%
2018 92.0 $ (1,923,765) $ 2,500,000

2019 93.0 $ (1,979,705) $ 2,500,000

2020 94.0 $ (2,179,186) $ 2,500,000

2021 95.0 $ (2,393,697) $ 2,500,000

LE (in Months) 30

The above chart is for illustrative purposes only. It should be used as a reference and no specific Return On Investment (“ROI”) is guaranteed or
implied. All calculations rely on assumptions about future circumstances. Actual returns may vary if the relied upon circumstances are not accurate.

Confidential Medical Summary

The Insured is a 89 year old male with an average life expectancy of 30 months. His primary impairment is
Chronic Lymphocytic Leukemia. He has had multiple surgeries which include, coronary PCI with multiple
stents. He has stage II malignant melanoma with multiple skin cancer excisions. He stopped smoking in 1980
and continues to use alcohol responsibly. He also has a history with bleeding ulcers. In 2012 he was he
received six months of chemotherapy and in 2013 he received radiation therapy. Doctors notes indicate that
he has a frail appearance with a BMX (body mass index) of 24.6. Medications include; ASA, Doxycycline,
Lasix, Levothyroxine and Pravastatin.

27 CONFIDENTIAL, NOT TO BE DUPLICATED

28 CONFIDENTIAL, NOT TO BE DUPLICATED

29 CONFIDENTIAL, NOT TO BE DUPLICATED

30 CONFIDENTIAL, NOT TO BE DUPLICATED

CONFIDENTIAL, NOT TO BE DUPLICATED

31

CONFIDENTIAL, NOT TO BE DUPLICATED

32

33 CONFIDENTIAL, NOT TO BE DUPLICATED

CONFIDENTIAL, NOT TO BE DUPLICATED

34

CONFIDENTIAL, NOT TO BE DUPLICATED

35

CONFIDENTIAL, NOT TO BE DUPLICATED

36

CONFIDENTIAL, NOT TO BE DUPLICATED

37

Policy ROI Illustration Wolfson

Date Calculator Prepared: 10/14/2015
ALSP2014-1271
Policy ID:
Multiplier
Months Underwriter
21 ST 10.16
LE 1 52 AVS 190

LE 2 75

LE 3

Full Policy Details

Insurance Company: Anico
Company Rating: A
Type of Death Benefit:
Face Amount (Death Benefit): FDB
Leveled or Optimized Annual Premium Expense: $7,000,000
Annual Premium Expense (Year 1): Optimized
DOB of Insured: $143,824
Age as of Date Prepared:
Gender: 1932
Longest LE (In Months): 83.3
Average LE (In Months): Male
75
64

Purchase Details

Years Escrowed For Premiums (Estimated): 6
Premiums Paid Through Date: 10/14/2021
Acquisition Cost: $3,499,101
Acquisition Cost as a Percentage of Face Amount:
49.99%

Estimated Return Including Premium Refunds/Calls

Amount Paid

Year Year Insured Cost (Includes Upon Maturity Gain/ Loss Yearly IRR
Age Escrow Reserve) (Includes Escrow
1 106.56%
2 Reserve) 42.45%
3 26.43%
4 2016 84.3 $ (3,499,101) $ 7,071,912 $ 3,572,811 19.16%
5 15.02%
6 2017 85.3 $ (3,499,101) $ 7,000,000 $ 3,500,899 12.35%
7 9.53%
8 2018 86.3 $ (3,499,101) $ 7,000,000 $ 3,500,899 6.27%
9 3.18%
10 2019 87.3 $ (3,499,101) $ 7,000,000 $ 3,500,899 0.20%
14.01%
2020 88.3 $ (3,499,101) $ 7,000,000 $ 3,500,899

2021 89.3 $ (3,499,101) $ 7,000,000 $ 3,500,899

2022 90.3 $ (3,890,233) $ 7,000,000 $ 3,109,767

2023 91.3 $ (4,756,180) $ 7,000,000 $ 2,243,820

2024 92.3 $ (5,775,820) $ 7,000,000 $ 1,224,180

2025 93.3 $ (6,917,359) $ 7,000,000 $ 82,641

LE (in Months) 64

The above chart is for illustrative purposes only. It should be used as a reference and no specific Return On Investment (“ROI”) is guaranteed or implied. All
calculations rely on assumptions about future circumstances. Actual returns may vary if the relied upon circumstances are not accurate.

Confidential Medical Summary

The insured is a 83.3 year old male with an average life expectancy of 64 months. He has a history of coronary artery
disease. He had a pulmonary embolism and stents implanted in 2014. The insured has had multiple falls in the past 5
years and sufferes from recurring dizziness from vertigo. He has a history of smoking and alcohol misuse. In
December he was noted for increased shortness of breath. His BMX (body mass index) is 26.5 and medications
include; Candesartan, Pantoprazole, Hydromorphone and Coumadin.

CONFIDENTIAL, NOT TO BE DUPLICATED

38

CONFIDENTIAL, NOT TO BE DUPLICATED

39

CONFIDENTIAL, NOT TO BE DUPLICATED

40

CONFIDENTIAL, NOT TO BE DUPLICATED

41

CONFIDENTIAL, NOT TO BE DUPLICATED

42

CONFIDENTIAL, NOT TO BE DUPLICATED

43

CONFIDENTIAL, NOT TO BE DUPLICATED

44

CONFIDENTIAL, NOT TO BE DUPLICATED

45

CONFIDENTIAL, NOT TO BE DUPLICATED

46

47 CONFIDENTIAL, NOT TO BE DUPLICATED

Policy ROI Illustration Cerullo

Date Calculator Prepared: Months Underwriter 1/22/2016
Policy ID: 76 AVS ALSP2014-1273
67 LSI
LE 1 Multiplier
LE 2
LE 3 185
275

Full Policy Details

Insurance Company: Allianz
Company Rating: A
Type of Death Benefit:
Face Amount (Death Benefit): FDB
Leveled or Optimized Annual Premium Expense: $8,500,000
Annual Premium Expense (Year 1): Optimized
DOB of Insured: $410,975
Age as of Date Prepared:
Gender: 1931
Longest LE (In Months): 85.1
Average LE (In Months): Female
76
72

Purchase Details

Years Escrowed For Premiums (Estimated): 5
Premiums Paid Through Date: 1/22/2021
Acquisition Cost: $5,990,161
Acquisition Cost as a Percentage of Face Amount:
70.47%

Estimated Return Including Premium Refunds/Calls

Amount Paid

Year Year Insured Cost (Includes Upon Maturity Gain/ Loss Yearly IRR
Age Escrow Reserve) (Includes Escrow
1 100.47%
2 Reserve) 36.61%
3 20.24%
4 2017 86.1 $ (5,990,161) $ 10,143,900 $ 4,153,739 12.82%
5 8.61%
6 2018 87.1 $ (5,990,161) $ 9,732,925 $ 3,742,764 5.90%
7 3.85%
8 2019 88.1 $ (5,990,161) $ 9,321,950 $ 3,331,789 1.72%
5.90%
2020 89.1 $ (5,990,161) $ 8,910,975 $ 2,920,814

2021 90.1 $ (5,990,161) $ 8,500,000 $ 2,509,839

2022 91.1 $ (6,401,136) $ 8,500,000 $ 2,098,864

2023 92.1 $ (6,884,892) $ 8,500,000 $ 1,615,108

2024 93.1 $ (7,682,892) $ 8,500,000 $ 817,108

LE (in Months) 72

The above chart is for illustrative purposes only. It should be used as a reference and no specific Return On Investment (“ROI”) is guaranteed or

implied. All calculations rely on assumptions about future circumstances. Actual returns may vary if the relied upon circumstances are not
accurate.

Confidential Medical Summary

The insured is an 85 year old female with Coronary Artery Disease, obstructive cardiomyopathy and
rheumatoid arthritis. Surgical history includes various excisions of Basal Cell Carcinoma (BCC) and
the insertion of a pacemaker. Medications include Alendronate, Diltiazem, Hydrocodone-
Acetaminophen, Labetalol and Methotrexate.

CONFIDENTIAL, NOT TO BE DUPLICATED

48

CONFIDENTIAL, NOT TO BE DUPLICATED

49


Click to View FlipBook Version